FARN
NEUTRALFaron Pharmaceuticals Announces Director Dealing
The pharmaceutical company has announced that its Non-Executive Chairman has purchased additional shares in the company.
Faron Pharmaceuticals Oy
207.50GBX
0.00%
Market Cap
251.45M
Volume
306
2% of avg
P/E Ratio
-7.98
EPS (TTM)
-0.26
Beta
1.18
Day Range
202.50p - 210.20p
52 Week Range
125.00p207.50p270.00p
207.50p
Upcoming Events
April 2, 2028
Maturity date for the first tranche of convertible bonds
FARN
NEUTRALFaron Pharmaceuticals Director Increases Stake
The pharmaceutical company announces a director has purchased additional shares in the business.
FARN
NEUTRALFaron Pharmaceuticals Founders Donate Shares to Foundation
The founders of the biotechnology company have donated a portion of their shares to an independent foundation.
FARN
NEUTRALFaron Pharmaceuticals Raises Funds to Satisfy Existing Obligations
The biotechnology company has raised funds to satisfy existing obligations, but details on the pricing and purpose of the raise are limited.
FARN
NEUTRALFaron Pharmaceuticals Approves Share Subscriptions for Debt Amortization
The biotechnology company has approved the exercise of special rights to issue new shares, raising €907,499 to amortize debt. The raise is moderately discounted, signaling some investor appetite but potential ongoing funding needs.
FARN
NEUTRALFaron Pharmaceuticals Issues Treasury Shares to Prepare for Convertible Bond Conversions
The biopharmaceutical company has issued 5 million treasury shares to prepare for potential future conversions of its convertible bonds, a move that could have both positive and negative implications for investors.
FARN
NEUTRALFaron Appoints New Chief Business Officer
The pharmaceutical company has appointed a new Chief Business Officer to strengthen its commercial strategy, business development and market assessment function.
FARN
NEUTRALFaron Pharmaceuticals Grants Options to Directors and Staff
The biopharmaceutical company has granted options to its directors and staff as part of its share option plan.
FARN
NEUTRALFaron Pharmaceuticals Announces Divestment of Shareholding
The biopharmaceutical company announces that an investor has sold its entire stake in the firm.
FARN
NEUTRALFaron Pharmaceuticals Announces Positive Phase II Results for Bexmarilimab in Higher-Risk MDS
The biopharmaceutical company reports positive Phase II trial results for its investigational therapy bexmarilimab in treating higher-risk myelodysplastic syndrome, a serious blood cancer.